Catalent creates new Advanced Delivery Technologies business unit

Published: 9-Jul-2013
Manufacturing Drug Delivery Pharmaceutical

Will combine the expertise of its Modified Release and Medication Delivery businesses


Catalent Pharma Solutions, a US-based global drug development and advanced delivery technology company, has combined its Modified Release and Medication Delivery businesses with the creation of a new business unit called Advanced Delivery Technologies.

This new unit will focus on new and proven drug delivery technologies, optimising the company’s multiple technologies, investment in capabilities, cross-platform R&D solutions and global commercial manufacturing network.

Catalent says this structure will also establish its Softgel Technologies, Advanced Delivery Technologies and Development & Clinical Services business units as global leaders in their respective markets.

Barry Littlejohns will head the new business unit as President. Littlejohns has more than 25 years of experience in the drug delivery industry spanning oral dose forms, parenteral delivery and biologics.

He said: ‘By bringing together talent and expertise from two proven teams, with our extensive intellectual property, technology and manufacturing platforms, we expect to partner with innovators around the world to deliver the most innovative, advanced and effective solutions to help bring more products to market faster and improve the efficacy of their treatments.’

The Advanced Delivery Technologies unit will operate eight development and manufacturing facilities around the world including those for fast dissolve technologies at Swindon, UK; controlled release technologies in Winchester, KY, US, which is currently undergoing a major expansion; the recently expanded Schorndorf, Germany site, and the advanced drug development centre in Somerset, NJ, US; the new Biologics centre of excellence at Madison, WI, US; advanced aseptic production in Woodstock, IL, US; and pre-filled syringe facilities in Brussels, Belgium and Limoges, France.

  • Companies:
  • Catalent
See more

You may also like

Manufacturing

Ardena acquires Catalent's US oral dose manufacturing facility, adding further bioanalytical services

Read more
The CRO/CDMO will now integrate its advanced late-stage and small-scale commercial oral drug product manufacturing services with an extended list of bioanalytical services, enhancing its offering to clients in the North American region

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Ardena acquires Catalent's US oral dose manufacturing facility, adding further bioanalytical services

The CRO/CDMO will now integrate its advanced late-stage and small-scale commercial oral drug product manufacturing services with an extended list of bioanalytical services, enhancing its offering to clients in the North American region
Manufacturing

Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation

Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its large-scale spray drying unit (GEA PSD-4) at its Boston (MA, US) facility
Manufacturing

Catalent expands integrated development, manufacturing and supply for modalities

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service
Manufacturing

Catalent adds cryogenic capabilities to support gene development

The facility in Shiga will include the storage, kitting, and distribution of advanced therapies at ultra-low temperatures for clinical trials
Manufacturing

Catalent begins $20 million construction project

The project creates space in the original building to accommodate the installation of a new, fully automatic bottle filling line
Distribution

Catalent enters commercial supply agreement

Since 2017, Harm Reduction Therapeutics has been working on a low-cost, OTC naloxone product to act as a critical tool to help stem the loss of life
Manufacturing

Catalent and Bhami announce licensing agreement

Catalent will be authorised to collaborate with its customers to evaluate BRL’s formulation technology
Subscribe now